There are 122 resources available
Adjuvant Treatment of Colon Cancer in 2021: Debate: 3 Months of CAPOX Should be The Standard of Care For All Stage 3 Colon Cancer Patients: No
Presenter: Takayuki Yoshino, Japan
Session: Adjuvant Treatment of Colon Cancer in 2021
Resources:
Slides
Webcast
Adjuvant Treatment of Colon Cancer in 2021: Debate: 3 Months of CAPOX Should be The Standard of Care For All Stage 3 Colon Cancer Patients: Discussion
Presenter: Alberto Sobrero, Italy
Session: Adjuvant Treatment of Colon Cancer in 2021
Resources:
Webcast
Adjuvant Treatment of Colon Cancer in 2021: Neoadjuvant Chemotherapy for dMMR Stage 2 and 3 Colon Cancer- My Approach!
Presenter: Julien Taieb, France
Session: Adjuvant Treatment of Colon Cancer in 2021
Resources:
Slides
Webcast
Adjuvant Treatment of Colon Cancer in 2021: Neoadjuvant Chemotherapy for dMMR Stage 2 and 3 Colon Cancer- My Approach!
Presenter: Harpreet Wasan, United Kingdom
Session: Adjuvant Treatment of Colon Cancer in 2021
Resources:
Slides
Webcast
Adjuvant Treatment of Colon Cancer in 2021: Neoadjuvant Chemotherapy for dMMR Stage 2 and 3 Colon Cancer- My Approach! Discussion
Presenter: Deborah Mukherji, Lebanon
Session: Adjuvant Treatment of Colon Cancer in 2021
Resources:
Webcast
Adjuvant Treatment of Colon Cancer in 2021: Colon Cancer Surveillance: How to Monitor for Recurrence, Current Guidelines, and Emerging Data for ctDNA vs CT/CEA
Presenter: Ramon Salazar, Spain
Session: Adjuvant Treatment of Colon Cancer in 2021
Resources:
Slides
Webcast
Adjuvant Treatment of Colon Cancer in 2021: Q&A
Presenter: Deborah Mukherji, Lebanon
Session: Adjuvant Treatment of Colon Cancer in 2021
Resources:
Webcast
LBA-4
Presenter: Yelena Janjigian, United States
Session: Session X: Esophageal and Gastric Cancers
Resources:
Webcast
O-15: Randomized, Phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup
Presenter: Jaffer Ajani,
Session: Session X: Esophageal and Gastric Cancers
Resources:
Webcast
LBA-5: Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer
Presenter: Zev Wainberg, United States
Session: Session X: Esophageal and Gastric Cancers
Resources:
Webcast